Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19917571 | 0.92 | F2 (0.52) | TDP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL23072576 | 0.90 | F2 (0.51) | TDP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL18612885 | 0.86 | TDP1 (0.55) | TDP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL21524659 | 0.85 | TDP1 (0.58) | TDP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL26585156 | 0.83 | TDP1 (0.56) | TDP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL21524702 | 0.81 | TDP1 (0.56) | TDP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL18736958 | 0.81 | TDP1 (0.61) | TDP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL23571711 | 0.81 | TDP1 (0.61) | TDP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL17662507 | 0.81 | TDP1 (0.61) | TDP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL19772947 | 0.81 | TDP1 (0.61) | TDP1F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057478-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | TDP1 2646/4885F2 3304/4885PRSS1 4369/4885 |
| US-10377742-B2 | AMPK-activating heterocyclic compounds and methods for using the same | PRKAG1, PRKAG2, PRKAB1 | TDP1 2646/4885F2 3304/4885PRSS1 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.